Secukinumab (Rheumatoid Arthritis) Forecast and MarketAnalysisReport Details:Published:November 2012No. of Pages: 45Price:...
- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the comp...
6.2.4 The discovery of curative therapies 246.2.5 Improved drug safety and efficacy profiles 246.3 Gap Analysis 256.4 Oppo...
Table 5: Overall Unmet Needs - Current Level of Attainment 22Table 6: Clinical Unmet Needs - Gap Analysis, 2012 26Table 7:...
Upcoming SlideShare
Loading in...5
×

Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis

317

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
317
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis"

  1. 1. Secukinumab (Rheumatoid Arthritis) Forecast and MarketAnalysisReport Details:Published:November 2012No. of Pages: 45Price: Single User License – US$6995Secukinumab (Rheumatoid Arthritis) Forecast and Market AnalysisSummaryGlobalData has released its new PharmaPoint Drug Evaluation report, Secukinumab (RheumatoidArthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with theNovember 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaitingapproval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’sSYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt todislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven oncethey enter the market.Novartis is developing a novel, subcutaneous, fully-human mAb IL-17A inhibitor, known assecukinumab (or AIN457), which is in Phase III clinical trials in various countries including US, EU,and Japan. It promotes inflammatory responses as it neutralizes IL-17A, resulting in the preventionof bone loss. Secukinumab is currently in clinical development for RA as well as for Crohn’sdisease, MS, psoriatic arthritis, ankylosing spondylitis, and psoriasis.Scope- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatmentguidelines as well as an overview on the competitive landscape.- Detailed information on Secukinumab including product description, safety and efficacy profilesas well as a SWOT analysis.- Sales forecast for Secukinumab for the top eight countries from 2011 to 2022.- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan andAustralia.Reasons to buy
  2. 2. - Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape forrheumatoid arthritis.- Effectively plan your M&A and partnership strategies by identifying drugs with the most promisingsales potential- Make more informed business decisions from insightful and in-depth analysis of Secukinumabperformance- Obtain sales forecast for Secukinumab from 2011 to 2022 in (the US, France, Germany, the UK,Italy, Spain, Japan and Australia)Get your copy of this report @http://www.reportsnreports.com/reports/213180-secukinumab-rheumatoid-arthritis-forecast-and-market-analysis.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 52 Introduction 62.1 Catalyst 62.2 Related Reports 73 Disease Overview 93.1 Etiology and Pathophysiology 93.1.1 Etiology 93.1.2 Pathophysiology 93.1.3 Prognosis 123.1.4 Quality of Life 123.2 Symptoms 134 Disease Management 144.1 Overview 144.2 Diagnosis 144.3 Treatment 165 Competitive Assessment 205.1 Overview 205.2 Strategic Competitor Assessment 206 Opportunity and Unmet Need 226.1 Overview 226.2 Unmet Needs 236.2.1 More rheumatologists in the field and physician knowledge of the disease 236.2.2 More cost-effective therapies through oral formulation and biosimilars 236.2.3 The development of predictive tests and discovery of biomarkers 24
  3. 3. 6.2.4 The discovery of curative therapies 246.2.5 Improved drug safety and efficacy profiles 246.3 Gap Analysis 256.4 Opportunities 266.4.1 Predictive tools for diagnosis and treatment 266.4.2 Target specificity 267 Pipeline Assessment 277.1 Overview 277.2 Promising Drugs in Clinical Development 288 Secukinumab (AIN457) 308.1 Overview 308.2 Efficacy 308.3 Safety 318.4 Dosing and Formulation 318.5 Potential Clinical Positioning 328.6 Potential Commercial Positioning 328.7 Pricing and Reimbursement 328.8 SWOT Analysis 328.9 Forecast 339 Appendix 349.1 Abbreviations 349.2 Bibliography 369.3 Methodology 399.4 Forecasting Methodology 399.4.1 Diagnosed Rheumatoid Arthritis Patients 399.4.2 Percent Drug-treated Patients 409.4.3 General Pricing Assumptions 409.4.4 Pricing of Pipeline agents 419.5 Physicians and Specialists Included in this Study 429.6 Primary Research - Prescriber Survey 429.7 About the Authors 439.7.1 Analysts 439.7.2 Global Head of Healthcare 449.8 About GlobalData 459.9 Contact Us 459.10 Disclaimer 451.1 List of TablesTable 1: Symptoms of Rheumatoid Arthritis 13Table 2: Treatment Guidelines for Rheumatoid Arthritis 17Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 19Table 4: Treatment Guidelines for Rheumatoid Arthritis 21
  4. 4. Table 5: Overall Unmet Needs - Current Level of Attainment 22Table 6: Clinical Unmet Needs - Gap Analysis, 2012 26Table 7: Rheumatoid Arthritis - Phase Pipeline, 2012 28Table 8: Comparison of Therapeutic Classes in Development for RA, 2012 29Table 9: Product Profile - Secukinumab 30Table 10: Secondary Endpoint Results for Secukinumab vs. Placebo at Weeks 24 and 52 31Table 11: Secukinumab SWOT Analysis, 2012 32Table 12: Global Sales Forecasts ($m) for Secukinumab 33Table 13: Physicians Surveyed, By Country 421.2 List of FiguresFigure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis 9Figure 2: Rheumatoid Arthritis Biologic Drug Targets 11Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria PointSystem 15Figure 4: Severity of Rheumatoid Arthritis 16Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations*18Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022 28Contact: sales@reportsandreports.com for more information.

×